Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
OPKO Health, Inc.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
ITEM 7.01. Regulation FD Disclosure.
On March 18, 2011, the Company issued a press release announcing the completion of the underwritten public offering of an additional 2,397,029 shares of common stock pursuant to the over-allotment exercise by the underwriters in connection with the Offering. The press release is furnished as Exhibit 99.1 hereto.
The information provided in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
ITEM 8.01 Other Events.
On March 18, 2011, in connection with the completion of its previously announced underwritten public offering of 27,000,000 shares of common stock (the Offering), OPKO Health, Inc. (the Company) completed, pursuant to the over-allotment option exercised by the underwriters, the underwritten public offering of an additional 2,397,029 shares of common stock at a price of $3.75 per share. The Company received approximately $8.5 million in net proceeds from the offering after underwriting fees.
ITEM 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.